Hemophilia A Treatment Gets Green Light
The US Food and Drug Administration (FDA) has approved a new treatment for hemophilia A.
Another Hemophilia Treatment Option
Patients with hemophilia B, a rare, inherited bleeding disorder, may soon have another treatment option.
New VTE Guidelines Released
The American College of Chest Physicians (CHEST) issued some new guidelines for the treatment of venous thromboembolism (VTE).
Before Cancer Surgery, Blood Thinners Appeared Safe
Cancer patients have enough to worry about — they shouldn't have to worry about the health effects of medications taken before cancer surgery. And new evidence suggests they may not have to.
Novel Blood Clot Rx Shows Potential
Antiplatelet medications, while highly effective, can put surgical patients at risk of serious bleeding. But a new, safer drug may be on the horizon.
New Rx Treats Most Common Inherited Bleeding Disorder
Patients with von Willebrand disease (VWD) lack a protein that's essential for healthy blood clotting. But a newly approved medication could help with that.
FDA Approves New von Willebrand Rx
The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).
New Indication for Pradaxa
RIDGEFIELD, Conn., November 23, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Pradaxa® (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip replacement surgery.
New Recommendations for Hemophilia Patients
The National Hemophilia Foundation (NHF) recently issued a new recommendation on inhibitor testing for patients with hemophilia A and B.
Modified Hemophilia Rx Approved
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.